Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05445401
Other study ID # STARS-GC06
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date August 1, 2022
Est. completion date June 30, 2026

Study information

Verified date July 2022
Source The First Hospital of Jilin University
Contact Meng Li
Phone 18569951013
Email lm17@mails.jlu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In this study, patients with traditional neoadjuvant gastric cancer were used as controls to explore whether the triple pre-rehabilitation interventions of exercise, nutrition and psychology during the neoadjuvant period before surgery could improve the functional reserve of neoadjuvant gastric cancer patients and accelerate postoperative recovery.


Description:

Internationally, pre-rehabilitation strategies have been widely used in surgery. Due to the late start of the concept of enhanced rehabilitation in my country, the research on pre-rehabilitation in my country is still in its infancy, and the research on pre-rehabilitation in gastric cancer is basically in a blank state. Domestic scholars have compared the rehabilitation of gastric cancer patients in the exercise-based pre-rehabilitation group and the postoperative rapid rehabilitation group, and found that the postoperative stress response, insulin resistance, and inflammatory response in the pre-rehabilitation group were lower than those in the conventional treatment group, and their nutritional status was improved. faster. The pre-rehabilitation model of comprehensive exercise, nutritional support and psychological intervention is rarely used in gastric cancer patients, and there is a lack of high-quality clinical data and related research. Neoadjuvant chemotherapy and neoadjuvant chemotherapy combined with immunotherapy are the current research hotspots in locally advanced gastric cancer. The current research studies focus on tumor regression and prognosis and survival. However, the preoperative treatment cycle of neoadjuvant gastric cancer patients is long. If there is a lack of long-term and continuous effective management and guidance during the neoadjuvant therapy, it is very easy to lead to nutritional and nutritional deficiencies after neoadjuvant therapy. The poor physical condition makes the patient suffer from physical and psychological pain. Therefore, we considered whether it is possible to carry out effective, convenient and economical rehabilitation training treatment for neoadjuvant gastric cancer patients before surgery, so as to prevent the occurrence of surgical risks and other complications in the preoperative stage, improve the functional reserve of neoadjuvant gastric cancer patients and respond to surgery. stimulated and accelerated postoperative recovery.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date June 30, 2026
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: 1. Voluntarily participate in clinical research, fully understand and inform this research and sign the Informed Consent Form (ICF), and are willing to follow and have the ability to complete all experimental procedures; 2. The age when signing the informed consent form is 18 to 65 years old, male or female; 3. Advanced gastric adenocarcinoma patients diagnosed with clinical stage II-III by CT, MRI, gastroscope and pathology (based on the 8th edition UICC/AJCC staging); 4. The function of major organs is normal; 5. No history of gastric cancer surgery, chemotherapy or immunotherapy; 6. Not accompanied by systemic infection requiring antibiotic treatment; 7. After general examination, it is planned to undergo neoadjuvant immunotherapy and neoadjuvant chemotherapy followed by surgery; 8. No contraindications related to CT and MRI examinations; 9. ECOG score of 0-2 points; Exclusion Criteria: 1. The patient has a history of chemotherapy and immunotherapy in the past; 2. The patient cannot undergo CT or MRI scan, or has artifacts that cannot be assessed; 3. The patient refuses to participate in the study; 4. Patients who are going to undergo or have previously received organ or bone marrow transplantation; 5. The patient is pregnant, breastfeeding or unable to take appropriate contraceptive measures; 6. Patients with mental illness or related medical history, such as: the patient cannot understand the relevant requirements of this study; 7. Patients with human immunodeficiency virus (HIV) infection, active pulmonary tuberculosis or other severe, acute and chronic diseases that may increase the risk of participating in research and research drugs, and who are judged by the investigator to be unsuitable for participating in clinical research; 8. Other relevant factors are considered unsuitable for participating in the research by the researcher.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Pre-rehabilitation
Triple pre-rehabilitation interventions of exercise, nutrition and psychology
Standard medical care
Traditional care

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
The First Hospital of Jilin University

Outcome

Type Measure Description Time frame Safety issue
Primary 6 minutes walking test The maximum distance the patient can walk on an unimpeded hard surface in six minutes. 1 month after surgery
Primary Scored Patient-Generated Subjective Global Assessment score Scored Patient-Generated Subjective Global Assessment(PG-SGA), PG-SGA consists of two parts: patient self-assessment and medical staff assessment. The specific contents include body weight, food intake, symptoms, activity and physical function, the relationship between disease and nutritional needs, metabolic needs, Physical examination and other 7 aspects, the first 4 aspects are evaluated by the patients themselves, and the last 3 aspects are evaluated by the medical staff. The overall evaluation includes qualitative evaluation and quantitative evaluation. Higher scores mean a worse outcome. 1 month after surgery
Primary DMSM score Distress Management Screening Measure(DMSM), is an assessment tool recommended by the US National Comprehensive Cancer Network for screening the level and possible causes of psychological pain. The DMSM questionnaire consists of two parts: the first part is the Psychological Distress Thermometer (DT). The second part is the problem list (PL), which contains 36 factors.Higher scores mean a worse outcome. 1 month after surgery
Secondary Quality of life score QLQ-C30 Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ-C30 ). 3 month after surgery
Secondary Quality of life score QLQ-STO22 Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires ( QLQ-STO22). 3 month after surgery
Secondary Postoperative skeletal muscle index of the third lumbar spine plane. Grip strength (Kg). 3 month after surgery
Secondary The rate of weight loss (=10%) . The rate of weight loss (=10%) . 3 month after surgery
Secondary The incidence of sarcopenia. The incidence of sarcopenia. 3 month after surgery
Secondary The ratio of actual ONS to recommended ONS. The ratio of actual ONS to recommended ONS. 3 month after surgery
Secondary Albumin Laboratory test: albumin (g/L) 3 month after surgery
Secondary Hemoglobin Laboratory test: hemoglobin (g/L) 3 month after surgery
Secondary Prealbumin. Laboratory test: prealbumin (g/L) 3 month after surgery
Secondary Incidence of adverse reactions during neoadjuvant therapy. Incidence of adverse reactions during neoadjuvant therapy. 1 month after surgery
Secondary Completion rate of neoadjuvant therapy for gastric cancer Number of completed courses/number of regimen courses 1 month after surgery
Secondary Surgery rate after neoadjuvant therapy for gastric cancer. Surgery rate after neoadjuvant therapy for gastric cancer. 1 month after surgery
Secondary TRG grading after neoadjuvant therapy for gastric cancer. TRG grading after neoadjuvant therapy for gastric cancer. 1 month after surgery
Secondary R0 resection rate R0 resection rate 1 month after surgery
Secondary Postoperative complication rate of grade IIIa or above. Postoperative complication rate of grade IIIa or above. 3 month after surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05551416 - The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
Completed NCT05518929 - Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients Phase 4
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT05536102 - The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy) Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT05415098 - Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT04082364 - Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer Phase 2/Phase 3
Withdrawn NCT03766607 - Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer Phase 2
Recruiting NCT04118114 - Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors Phase 2
Completed NCT01924533 - Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer. Phase 3
Terminated NCT01641939 - A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer Phase 2/Phase 3
Recruiting NCT05107674 - A Study of NX-1607 in Adults With Advanced Malignancies Phase 1
Active, not recruiting NCT04908813 - Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04249739 - Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive Phase 2
Recruiting NCT05514158 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG) Phase 1
Recruiting NCT04931654 - A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer Phase 1/Phase 2
Recruiting NCT03175224 - APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Phase 2